MDM2 Inhibitor Breaks Through in Trial of Liposarcoma, Other Advanced Malignancies

(MedPage Today) -- Almost half of patients with advanced solid tumors or lymphomas experienced disease control with a drug that reactivates the TP53 tumor suppressor, a first-in-human study showed. Overall, the oral murine double minute-2 (MDM2...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news